Sequenom Aiming to Submit PMA Application to FDA for T21 Test by End of 2012

The company is currently working to "define a clinical study that would be acceptable to the FDA," Sequenom's CEO Harry Hixson said at the Jefferies Global Healthcare conference in New York.

Full-text access for premium subscribers only. Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.